Omnicell (OMCL) Q2 2024 earnings summary

Executive summary

• Q2 2024 results exceeded guidance, with revenue at $277 million, driven by innovation in the XT platform and recurring revenue growth, despite a 7% year-over-year decline due to challenging health system conditions and XT Series replacement cycle timing.

• Completed a holistic business review, identifying operational synergies, cost optimization, and process streamlining opportunities.

• Advanced Services and recurring revenue are key growth drivers, targeted to reach 21% of total revenue in 2024.

• Maintains a strong balance sheet, supporting ongoing investment in innovation and long-term growth.

• Macroeconomic and industry conditions are showing early improvement, supporting demand for medication management solutions.

Financial highlights

• Q2 2024 total revenue: $277 million, up 12% sequentially, down 7% year-over-year; GAAP net income: $4 million ($0.08 per share); non-GAAP EPS: $0.51; non-GAAP EBITDA: $40 million.

• Non-GAAP gross margin: 44.2% (down 260 bps year-over-year, up 440 bps sequentially); GAAP gross margin: 41%.

• Cash and equivalents: $557 million at quarter end, up from $512 million prior quarter; liquidity: $907 million including $350 million revolver.

• Non-GAAP free cash flow: $45 million; operating cash flow for H1 2024: $108.7 million.

• Inventory: $93 million, down $10 million sequentially, including $5.4–$6 million write-down from RDS restructuring.

Outlook and guidance

• FY 2024 revenue expected: $1.07–$1.11 billion; non-GAAP EBITDA: $105–$125 million; non-GAAP EPS: $1.20–$1.50.

• Q3 2024 revenue guidance: $275–$285 million; non-GAAP EPS: $0.34–$0.44.

• FY 2024 bookings expected: $775–$875 million; product revenue: $610–$630 million; service revenue: $460–$480 million; Advanced Services: $230–$240 million.

• Second half 2024 revenue expected to follow historic seasonal patterns, slightly above first half.

• Beginning 2025, will provide product bookings and annual recurring revenue metrics.